RedHill Biopharma Ltd.

RDHL

US7574682024

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-17 pm EDT			5-day change	1st Jan Change
0.4736 ^USD	-1.89%		+3.34%	-67.56%

May. 06	Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	MT
May. 06	RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	CI

Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021

February 17, 2022 at 09:32 am EST

RedHill Biopharma Ltd. provided earnings guidance for fourth quarter of 2021. For the quarter, the company record Q4/2021 total net revenues estimated to be in the range of $22-24 million vs. $21.6 million in Q3/2021 and $21.5 in Q4/2020.

Latest news about RedHill Biopharma Ltd.

Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib	May. 06	MT
RedHill Biopharma Ltd. Announces New Opaganib Chinese Patent against Ebola Virus Valid Through 2035	May. 06	CI
RedHill Biopharma Ltd Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study	Apr. 24	CI
RedHill Biopharma Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 08	CI
RedHill Biopharma Ltd. cancelled the transaction announced on March 8, 2023	Mar. 27	CI
Redhill Biopharma Says Talicia Gets New US Patent to Treat Helicobacter Pylori Infection	Mar. 11	MT
U.S. government Selects RedHill Biopharma Ltd.'s Opaganib for Evaluation by BARDA and NIH Countermeasures Programs	Mar. 05	CI
Redhill Biopharma Ltd. Announces New Publication of Data from Multiple Experiments in the International Journal of Molecular Sciences	Feb. 20	CI
Redhill Biopharma Closes $8 Million Registered Direct Offering of American Depositary Shares	Jan. 26	MT
RedHill Biopharma to Seek Acquisitions	Jan. 26	CI
ADRs Close Higher; Addex Therapeutics Climbs 21%	Jan. 25	DJ
Top Midday Decliners	Jan. 25	MT
Redhill Biopharma Launches $8 Million Offering of American Depositary Shares; Stock Falls	Jan. 25	MT
ADRs Close Higher, Evaxion Biotech A/S Climbs 113.4%	Jan. 24	DJ
Sector Update: Health Care Stocks Retreat Late Afternoon	Dec. 20	MT
Sector Update: Health Care Stocks Mixed in Wednesday Afternoon Trading	Dec. 20	MT
Redhill Says Opaganib, RHB-107 Combinations With Remdesivir Show 'Robust Synergistic Effect' Against Ebola; Shares Rise	Dec. 20	MT
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola	Dec. 20	CI
ADRs End Lower, Redhill Biopharma Ltd. Declines 22.6%	Dec. 06	DJ
U.S.-LISTED SHARES OF REDHILL BIOPHARMA RISE 2.4% ON ADDITIONAL…	Dec. 04	RE
Redhill Biopharma Says it Received $4.8 Million in Additional Funds for Study of Early COVID-19 Treatment	Dec. 04	MT
ADRs Close Higher; Akso Health Group Climbs 24%	Dec. 01	DJ
ADRs Close Higher; Incannex Healthcare Inc. Climbs 723.7%	Nov. 30	DJ
Top Premarket Decliners	Nov. 30	MT
ADRs End Flat; Sunlands Technology Group Climbs 31%	Nov. 29	DJ

Chart RedHill Biopharma Ltd.

Duration

Period

More charts

Company Profile

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelersâ diarrhea. RedHillâs clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Sector

Pharmaceuticals

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
REDHILL BIOPHARMA LTD.	-67.56%	15.09M
CSL LIMITED	-2.32%	90.45B
SAMSUNG BIOLOGICS CO.,LTD.	+3.68%	41.45B
BIOGEN INC.	-10.90%	33.57B
UCB	+58.05%	25.73B
BIOMARIN PHARMACEUTICAL INC.	-19.56%	14.73B
INCYTE CORPORATION	-9.06%	12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.34%	11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.53%	11.44B
SWEDISH ORPHAN BIOVITRUM AB	+3.75%	8.79B

Biopharmaceuticals